CN106928242A - 具有生物活性的钴配合物及其制备方法 - Google Patents
具有生物活性的钴配合物及其制备方法 Download PDFInfo
- Publication number
- CN106928242A CN106928242A CN201710194977.5A CN201710194977A CN106928242A CN 106928242 A CN106928242 A CN 106928242A CN 201710194977 A CN201710194977 A CN 201710194977A CN 106928242 A CN106928242 A CN 106928242A
- Authority
- CN
- China
- Prior art keywords
- complex
- cobalt
- pranoprofen
- preparation
- room temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 150000004700 cobalt complex Chemical class 0.000 title claims description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 21
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960003101 pranoprofen Drugs 0.000 claims abstract description 14
- 150000001868 cobalt Chemical class 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 8
- 239000013078 crystal Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 6
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 claims description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 2
- 238000001027 hydrothermal synthesis Methods 0.000 claims description 2
- 229960001680 ibuprofen Drugs 0.000 claims description 2
- JKQOBWVOAYFWKG-UHFFFAOYSA-N molybdenum trioxide Chemical compound O=[Mo](=O)=O JKQOBWVOAYFWKG-UHFFFAOYSA-N 0.000 claims 1
- JBJWASZNUJCEKT-UHFFFAOYSA-M sodium;hydroxide;hydrate Chemical compound O.[OH-].[Na+] JBJWASZNUJCEKT-UHFFFAOYSA-M 0.000 claims 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 claims 1
- -1 polytetrafluoroethylene Polymers 0.000 abstract description 4
- 229920001343 polytetrafluoroethylene Polymers 0.000 abstract description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 2
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 abstract 1
- 239000003446 ligand Substances 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 239000002184 metal Substances 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229910020647 Co-O Inorganic materials 0.000 description 1
- 229910020676 Co—N Inorganic materials 0.000 description 1
- 229910020704 Co—O Inorganic materials 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 150000001869 cobalt compounds Chemical class 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical class [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- PFUVRDFDKPNGAV-UHFFFAOYSA-N sodium peroxide Chemical compound [Na+].[Na+].[O-][O-] PFUVRDFDKPNGAV-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
具有生物活性的钴配合物及其制备方法，涉及化学配合物及其制备方法，以钴盐、普拉洛芬和氢氧化钠，依照1∶2∶2的摩尔比在水热条件下反应，并获得目标配合物；制备步骤是：将钴盐、氢氧化钠、普拉洛芬和水的混合物，在室温下搅拌三十分钟，随后把混合物转移到反应釜聚四氟乙烯内胆 ( 体积25‑50mL)中，再放置于70‑180℃烘箱中恒温10－96小时，然后降温到室温，制得Co(L)2紫红色块状晶体。制备得的配合物结构明确，具有药用价值。
Description
技术领域
发明涉及化学配合物及其制备方法，特别是涉及具有生物活性的钴配合物及其制备方法。
背景技术
金属配合物具有高效、低毒、抗菌活性的药理作用，其中以药物作为配体的研究居多。在结构方面，由于药物分子中大部分都含有杂原子如N原子或O氧原子，这些原子上都有孤对电子，容易与过渡金属离子键合，形成六配位八面体结构。在性质方面，近年来基于药物配体的配合物具有较高的临床应用价值，基于药物金属配合物在抗菌、消炎及方面的研究工作同样引起关注，并且关于它们的结构、抗菌活性也被逐渐深入研究。由布洛芬、阿司匹林、萘普生和吲哚美辛非甾体抗炎药作为配体分别构建了钌（II，III）配合物，这些配合物显示了肿瘤细胞增殖的强抑制作用。某些含氧化呋吨为配体的铂（II）配合物呈现出明显的抗肿瘤作用。一般来说，金属配位化合物通常表现出较高的活性。因而基于药物配体的金属配合物的深入研究和探索也成为一种挑战。普拉洛芬具有消炎止痛的功效，已经广泛用于类风湿性关节炎和眼科领域。我们用钴的化合物与普拉洛芬合成了一个新型的金属配合物，该配合物具有抗菌活性，能有效抑制革兰氏阳性菌和革兰氏阴性菌，也为深入理解抗菌作用和机理提供了有价值的信息。
发明内容
本发明的目的在于提供一种具有生物活性的钴配合物及其制备方法，该方法采用低温水热合成技术，将过渡金属钴盐与普拉洛芬和氢氧化钠按照配比反应，得到目标金属配位化合物。
本发明的目的是通过以下技术方案实现的：
具有生物活性的钴配合物，为一种药用价值的配位化合物，该配合物的摩尔配比为：以钴盐、普拉洛芬、氢氧化钠按照1∶2∶2 的摩尔比。
具有生物活性的钴配合物的制备方法，所述方法包括以下制备步骤：将钴盐、普拉洛芬、氧氧化钠和水的混合物，在室温下搅拌三十分钟，随后把混合物转移到水热反应釜聚四氟乙烯内胆、体积25-50mL中，在70-180℃条件下恒温，然后降温直到室温，制得目标配位化合物普拉洛芬根合钴(II)紫色块状晶体。
附图说明
图1为配位化合物Co(L)2的分子结构图，Co-O键长在1.935-2.044 Å范围内，Co-N键长为2.074 Å。
图2为配位化合物Co(L)2的二维结构图。
图3为配位化合物Co(L)2的堆积结构图。
具体实施方式
钴配合物Co(L)2(HL=普拉洛芬根) 的合成方法。本发明配合物Co(L)2单晶的制备方法及其结构，属于药物化学中的一种单晶化合物的制备方法及其结构，该配合物Co(L)2单晶中：L代表普拉洛芬根。该方法以普拉洛芬配体与中心离子Co(II)配位，即可获得目标配合物Co(L)2。该方法将钴盐、配体普拉洛芬和氢氧化钠在水热条件下进行反应（摩尔比为1∶2∶2）。制备得的配合物组成和分子结构明确，并用IR等手段进行表征，具有潜在的药物应用价值。
Co(L)2的制备实例：将钴盐(0.2-0.35mmol)、普拉洛芬(0.40-0.7mmol)、氢氧化钠(0.40-0.70 mmol) 和水(10-15mL)的混合物，在室温下置于反应釜聚四氟乙烯内胆 ( 体积25-50mL)中搅拌三十分钟，盖好反应釜盖；然后将装有反应物的反应釜放置于70-180℃烘箱中恒温10-96小时天后，降温直到室温，得到规则紫色块形产物。
Claims (2)
1.一种钴配合物，为一种药用价值的配位化合物，其特征在于，该配合物的摩尔配比为：以钴盐、普拉洛芬、氢氧化钠按照1∶2∶2的摩尔比，配位化合物的结构式如下：
2.一种钴配合物的制备方法，其特征在于，所述方法包括以下制备步骤：将钴盐、普拉洛芬、氧氧化钠和水的混合物，在室温下搅拌三十分钟，随后把混合物转移到水热反应釜聚四氟乙烯内胆、体积25-50mL中，在70-180℃条件下恒温，然后降温直到室温，制得目标配位化合物普拉洛芬根合钴(II)紫色块状晶体。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710194977.5A CN106928242A (zh) | 2017-03-29 | 2017-03-29 | 具有生物活性的钴配合物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710194977.5A CN106928242A (zh) | 2017-03-29 | 2017-03-29 | 具有生物活性的钴配合物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106928242A true CN106928242A (zh) | 2017-07-07 |
Family
ID=59425389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710194977.5A Pending CN106928242A (zh) | 2017-03-29 | 2017-03-29 | 具有生物活性的钴配合物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106928242A (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007109844A1 (en) * | 2006-03-24 | 2007-10-04 | Medical Therapies Limited | Anti-inflammatory metal complexes |
-
2017
- 2017-03-29 CN CN201710194977.5A patent/CN106928242A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007109844A1 (en) * | 2006-03-24 | 2007-10-04 | Medical Therapies Limited | Anti-inflammatory metal complexes |
Non-Patent Citations (2)
| Title |
|---|
| 王允飞: "以解热镇痛药酮洛芬为配体合成钴配合物的晶体结构及表征", 《化学与黏合》 * |
| 谢桂泉，等: "若干d3过渡金属的布洛芬配合物的合成及其性质的研究", 《暨南理医学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nakhaei et al. | Antibacterial activity of three zinc-terephthalate MOFs and its relation to their structural features | |
| Supriya et al. | A cyclic supramolecular (H 2 O) 4 cluster in an unusual Fe 3 complex that aggregates to {Fe 3} n with a zig-zag chainlike structure | |
| Uvarova et al. | Nickel (II) complexes with 2-Hfur and N-donors: The magnetic effects of the structural variations, thermal properties and antimycobacterial activity against Mycolicibacterium smegmatis | |
| CN109232567A (zh) | 四氯合铜-联吡啶季铵盐及其制备方法与应用 | |
| Alamier et al. | Characterization, crystal structure, and quantum chemical parameters of diaqua bis-(2-hydroxyiminopropanoato) iron (II): A comparative study | |
| CN107827914B (zh) | 一种铜席夫碱配合物及其制备方法和应用 | |
| Kendin et al. | A 3D-coordination polymer assembled from copper propionate paddlewheels and potassium propionate 1D-polymeric rods possessing a temperature-driven single-crystal-to-single-crystal phase transition | |
| Iqbal et al. | Synthesis, characterization, structural elucidation, molecular docking and antidiabetic studies of 1, 10-phenanthroline based mononuclear Cu (II) and Zn (II) complexes | |
| Nie et al. | Synthesis and structure of a polymeric 1, 3-benzenedicarboxylato complex of Mn (II) with phenanthroline | |
| Yue et al. | pH-dependent assembly of metal–organic hybrid compounds based on octamolybdates and a new flexible multidentate ligand | |
| CN106928242A (zh) | 具有生物活性的钴配合物及其制备方法 | |
| Tan et al. | Bifunctional tetrazole–carboxylate ligand based Zn (ii) complexes: synthesis and their excellent potential anticancer properties | |
| CN105777786A (zh) | 一种手性苯甲酸锌配合物晶体及合成方法 | |
| Padhi et al. | Synthesis, structure, thermal studies on Zn (II), Cd (II) complexes of N-(2-pyridylmethyl) pyridine-2-carbaldimine and N-(2-pyridylmethyl) pyridine-2-methylketimine | |
| Zhang et al. | Microwave-assisted synthesis, crystal structures, and in vitro antibacterial studies of zinc (II) and nickel (II) complexes with Schiff bases | |
| Sha et al. | Ligation of the quinolone antibacterial agent pipemidic acid to Keggin polyoxotungstates | |
| Balakrishnan et al. | A one-pot solid-state synthesis of MgO nanoparticles and their catalytic, biological, and electrochemical sensor activities: hexaaquamagnesium (ii) bis (6-oxo-1, 6-dihydropyridine-3-carboxylate) as a tool | |
| CN107043354A (zh) | 一种具有抗真菌活性的2‑苯并咪唑基苯甲酸铜配合物及制备方法 | |
| CN107652329A (zh) | 一种具有抗癌活性的离子型铱配合物及其制备方法、应用 | |
| He et al. | Syntheses and crystal structures of three new Zn (II) complexes constructed by homophthalate and diimine ligands | |
| Jittipiboonwat et al. | Crystal structure and photoluminescent properties of a new EuIII–phthalate–acetate coordination polymer | |
| Gong et al. | Synthesis and crystal structure of a novel organic–inorganic hybrid hexavanadate [(phen) 4V6O12 (CH3OH) 4]· 2CH3OH· 4H2O | |
| Chen et al. | Syntheses, characterization, and luminescent properties of four alkaline earth metal–organic frameworks based on two similar N-containing carboxylates | |
| Razmara et al. | Single-crystal structure feature of a new polymer based on Bi (III) as an antibacterial agent | |
| Gao et al. | Poly [[diaquabarium (II)]-μ5-m-phenylenedioxydiacetato]: a three-dimensional barium (II) coordination polymer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170707 |